[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-378389-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-378389-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","mrtx1719-is-an-mta-cooperative-prmt5-inhibitor-exhibits-synthetic-lethality-in-preclinical-models-and-patients-with-mtap-deleted-cancer","MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor - Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer","","MRTX1719 is a small-molecule PRMT5 inhibitor developed to exploit synthetic lethality in MTAP-deleted cancers. It selectively inhibits PRMT5 in the presence of elevated MTA found in MTAP del models, suppressing PRMT5-dependent activity and cell viability with >70-fold selectivity in HCT116 MTAP del versus wild-type cells. The compound shows dose-dependent antitumor activity and PRMT5-dependent SDMA inhibition in MTAP del tumors, with minimal effects in MTAP wild-type xenografts and hematopoietic cells.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/mrtx1719-is-an-mta-cooperative-prmt5-inhibitor-exhibits-synthetic-lethality-in-preclinical-models-and-patients-with-mtap-deleted-cancer/378389/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/mrtx1719-is-an-mta-cooperative-prmt5-inhibitor-exhibits-synthetic-lethality-in-preclinical-models-and-patients-with-mtap-deleted-cancer/378389.png","ImageObject",300,407,{"name":42,"@type":43},"Mimi","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-14","2026-09-24",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How does MRTX1719 selectively inhibit PRMT5 in MTAP-deleted cancers?","Question",{"text":63,"@type":64},"MRTX1719 selectively inhibits PRMT5 when MTA is elevated, a condition characteristic of MTAP del cancers. It suppresses PRMT5-dependent activity and cell viability with strong selectivity versus MTAP wild-type cells.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What evidence shows MRTX1719 has antitumor effects in preclinical models?",{"text":68,"@type":64},"MRTX1719 demonstrates dose-dependent antitumor activity and inhibits PRMT5-dependent SDMA modification in MTAP del tumors. It also shows marked antitumor activity across a panel of xenograft models at well-tolerated doses.",{"name":70,"@type":61,"acceptedAnswer":71},"What clinical activity was observed in early patient studies?",{"text":72,"@type":64},"Early signs of clinical activity were reported from a phase I/II study, including objective responses in patients with MTAP del melanoma, gallbladder adenocarcinoma, mesothelioma, non-small cell lung cancer, and malignant peripheral nerve sheath tumors.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},378389,1790316311,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":118,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":104,"preview_page_count":33,"preview_urls":145},2336477974920,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","RESEARCH ARTICLE  \nMRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethalityin Preclinical Models and Patients with  \nMTAP-Deleted Cancer   \nLars D. Engstrom1, Ruth Aranda1, Laura Waters1, Krystal Moya1, Vickie Bowcut1, Laura Vegar1, David Trinh1, Allan Hebbert1, Christopher R. Smith1, Svitlana Kulyk1, J. David Lawson1, Leo He2, Laura D. Hover2, Julio Fernandez-Banet2, Jill Hallin1, Darin Vanderpool1, David M. Briere1, Alice Blaj1, Matthew A. Marx1, Jordi Rodon3, Michael Offin4, Kathryn C. Arbour4, Melissa L. Johnson5,  \nDavid J. Kwiatkowski6,7, Pasi A. Jänne6,7, Candace L. Haddox6, Kyriakos P. Papadopoulos8, Jason T. Henry9, Konstantinos Leventakos10, James G. Christensen1, Ronald Shazer1, and Peter Olson1  \n ABSTRACT  Previous studies implicated protein arginine methyltransferase 5 (PRMT5) as a synthetic lethal target for MTAP-deleted (MTAP del) cancers; however, the pharmaco  \nlogic characterization of small-molecule inhibitors that recapitulate the synthetic lethal phenotype has not been described. MRTX1719 selectively inhibited PRMT5 in the presence of MTA, which is elevated in MTAP del cancers, and inhibited PRMT5-dependent activity and cell viability with >70-fold selectivity in HCT116 MTAP del compared with HCT116 MTAP wild-type (WT) cells. MRTX1719 demonstrated dose-dependent antitumor activity and inhibition of PRMT5-dependent SDMA modification in MTAP del tumors. In contrast, MRTX1719 demonstrated minimal effects on SDMA and viability in MTAP WT tumor xenografts or hematopoietic cells. MRTX1719 demonstrated marked antitumor activity across a panel of xenograft models at well-tolerated doses. Early signs of clinical activity were observed including objective responses in patients with MTAP del melanoma, gallbladder adenocarcinoma, mesothelioma, non–small cell lung cancer, and malignant peripheral nerve sheath tumors from the phase I/II study.  \nSIGNIFICANCE: PRMT5 was identified as a synthetic lethal target for MTAP del cancers; however, previous PRMT5 inhibitors do not selectively target this genotype. The differentiated binding mode of MRTX1719 leverages the elevated MTA in MTAP del cancers and represents a promising therapy for the ∼ 10% of patients with cancer with this biomarker.  \nSee related commentary by Mulvaney, p. 2310.  \nIllustration by Bianca Dunn  \nINTRODUCTION  \nTumor suppressor genes lost via biallelic deletions cannot be directly targeted per se; however, cancers with tumor suppressor alterations may exhibit vulnerabilities that can be exploited for the treatment of cancer. Functional genomic screens in  \n1Mirati Therapeutics, Inc., San Diego, California. 2Monoceros Biosciences LLC, San Diego, California. 3Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. 4Department of Medicine, Division of Clinical Research, Memorial Sloan Kettering Cancer Center, New York, New York. 5Sarah Cannon Research Institute Tennessee Oncology, Nashville, Tennessee. 6Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. 7Harvard Medical School, Boston, Massachusetts. 8South Texas Accelerated Research Therapeutics, San Antonio, Texas. 9Sarah Cannon Research Institute at HealthOne, Denver, Colorado.  \n10Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota.  \nmolecularly annotated cancer cell lines have cataloged the dependencies of thousands of genes and are particularly useful for the identification of long-sought synthetic lethal targetsand exploitable vulnerabilities for tumor suppressor–altered states (1, 2). Homozygous deletion of the CDKN2A region  \nCorresponding Author: Peter Olson, Mirati Therapeutics, Inc., 3545 Cray  \nCourt, San Diego, CA 92121. E-mail: [olsonp@mirati.com](olsonp@mirati.com)  \nCancer Discov 2023;13:2412–31  \ndoi: 10. 1158/2159-8290 . CD-23-0669  \nThis open access article is distributed under the Creative Commons AttributionNonCommercial-NoD","cbCaiujgrQpABKAL","https://ap.wps.com/l/cbCaiujgrQpABKAL","pdf",20427235,"English","# Abstract\n# Significance\n# Introduction","[{\"question\":\"How does MRTX1719 selectively inhibit PRMT5 in MTAP-deleted cancers?\",\"answer\":\"MRTX1719 selectively inhibits PRMT5 when MTA is elevated, a condition characteristic of MTAP del cancers. It suppresses PRMT5-dependent activity and cell viability with strong selectivity versus MTAP wild-type cells.\"},{\"question\":\"What evidence shows MRTX1719 has antitumor effects in preclinical models?\",\"answer\":\"MRTX1719 demonstrates dose-dependent antitumor activity and inhibits PRMT5-dependent SDMA modification in MTAP del tumors. It also shows marked antitumor activity across a panel of xenograft models at well-tolerated doses.\"},{\"question\":\"What clinical activity was observed in early patient studies?\",\"answer\":\"Early signs of clinical activity were reported from a phase I/II study, including objective responses in patients with MTAP del melanoma, gallbladder adenocarcinoma, mesothelioma, non-small cell lung cancer, and malignant peripheral nerve sheath tumors.\"}]","MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor - Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer | PDF",1790229831,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4fb0ebb986fb0a78bfcde1874dae810e.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f333c1722d18b8c7cac643393f961a70.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e4a825b3f06b1909eaf58018a1832446.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7febca699d14a09a70423dc7e05a9a0f.webp",980,1301]